Editas Medicine Inc. (EDIT)
1.27
0.13 (11.40%)
At close: Jan 15, 2025, 10:29 AM
undefined% (undefined)
| Bid | 1.26 |
| Market Cap | 104.84M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.54 |
| PE Ratio (ttm) | -0.5 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 1.27 |
| Volume | 753,662 |
| Avg. Volume (20D) | 2,683,032 |
| Open | 1.19 |
| Previous Close | 1.14 |
| Day's Range | 1.19 - 1.28 |
| 52-Week Range | 1.12 - 11.58 |
| Beta | undefined |
About EDIT
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, whic...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 3, 2016
Employees 265
Stock Exchange NASDAQ
Ticker Symbol EDIT
Website https://www.editasmedicine.com
Analyst Forecast
According to 14 analyst ratings, the average rating for EDIT stock is "Hold." The 12-month stock price forecast is $7.5, which is an increase of 490.55% from the latest price.
Buy 42.86%
Hold 42.86%
Sell 7.14%
Next Earnings Release
Editas Medicine Inc. is scheduled to release its earnings on Feb 26, 2025,
before market opens.
Analysts project revenue of $19.97M, reflecting a -66.74% YoY shrinking and earnings per share of -0.58, making a 152.17% increase YoY.
Analysts project revenue of $19.97M, reflecting a -66.74% YoY shrinking and earnings per share of -0.58, making a 152.17% increase YoY.
1 month ago ·
Source
-23.81%
Editas Medicine shares are trading lower after Sti...
Unlock content with
Pro Subscription
1 month ago ·
Source
-5.03%
Editas Medicine shares are trading higher after the company announced plans to transition to an in vivo focus and initiated a reduction in headcount, aiming to eliminate approximately 65% of its workforce over the next six months.
